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ABSTRACT
Purpose. The aim of this study was to help with the pro-
cess of selecting patients with advanced ovarian cancer to
undergo cytoreductive surgery (CRS) with hyperthermic
intraperitoneal chemotherapy (HIPEC) by analyzing out-
come data at distinct clinical time points reflecting the
natural history of the disease.
Methods. In a retrospective Italian multicenter study investi-
gating patients with advanced ovarian cancer who underwent
CRS plus HIPEC between 1998 and 2014, we analyzed data for
consecutive patients at eight treatment time points: primary
debulking surgery (PDS); interval debulking surgery after par-
tial response, after no response, and after a pathologic complete
response to neoadjuvant chemotherapy; first recurrence with a
progression-free interval[12,\12 months, or[12 months in
patients who underwent further chemotherapy before CRS and
HIPEC; and patients who underwent two or more CRS proce-
dures and chemotherapy lines before CRS and HIPEC.
Results. The 511 enrolled patients underwent 3373 proce-
dures; 72.6% achieved complete cytoreduction, with an overall
major morbidity of 17.4%. At a median follow-up of
53.8 months, overall survival (OS) was 54.2 months (95%
confidence interval [CI] 44–58.4) and progression-free (PFS)
survival was 16.6 months (95% CI 14.7–19.1). Outcome
analysis in patients in whom CRS plus HIPEC was used for
primary advanced cancer or recurrent ovarian cancer showed
significant differences in OS and PFS according to the time -
points analyzed. Multivariate analysis identified completeness
of CRS, Peritoneal Cancer Index, and the times when patients
underwent CRS plus HIPEC as independent prognostic factors.
Conclusions. This selective information on survival
should help in interpreting the findings from ongoing ran-
domized studies focusing on CRS plus HIPEC in patients
with advanced ovarian cancer.
Most patients with ovarian cancer are diagnosed at an
advanced stage, and at least 75% of cases involve the
peritoneum, frequently with ascites or subocclusion.1,2
Even though survival rates have improved over recent
years,2–5 more than 70% of these patients have recurrent
disease within 5 years.6–8
Given that ovarian disease remains confined within the
peritoneal cavity for most of its clinical history, attention has
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turned towards aggressive locoregional therapy combining
hyperthermic intraperitoneal chemotherapy (HIPEC) with
maximal cytoreductive surgery (CRS) [peritonectomy pro-
cedures],9–15 an approach generally used in centers
specifically involved in treating primary peritoneal tumors or
peritoneal metastases from various origins, namely peritoneal
surface malignancies (PSM).16–18 Despite numerous studies,
including a randomized controlled trial and meta-analysis,
showing better outcomes with acceptable morbidity after
CRS combined with HIPEC than after traditional treatments
for advanced ovarian cancer,13,14 wide skepticism persists
about whether HIPEC really adds value to CRS alone, as well
as concern that it might increase complications.19,20 A major
hindrance to more widespread use of HIPEC combined with
CRS in treating advanced ovarian cancer is that previous case
series have mainly analyzed outcomes for two treatment
settings (primary and recurrent disease), disregarding the
long natural history of disease, multiple clinical scenarios and
progressive disease stages.21,22 Hence, while we await the
results from the numerous ongoing prospective randomized
trials expected to provide data on the role of HIPEC combined
with CRS in primary and recurrent disease,23 we now need to
analyze outcome data at non-overlapping clinical time points
related to patients’ responses to neoadjuvant chemotherapy
(NACT) or adjuvant chemotherapy, and to the complex
problems caused by repeated chemotherapy lines or CRS for
multiple recurrence or disease progression. This valuable
new information could help in the process of selecting
patients to undergo CRS and HIPEC combined, and specify
when the integrated procedure would have the greatest benefit
on outcomes.
We designed this multicenter study to investigate a large
series of patients with advanced ovarian cancer treated in
the major Italian centers experienced in treating PSM with
CRS and HIPEC combined. Our specific aim was to assess
the results of the integrated procedure obtained in patients
grouped according to primary and recurrent disease, and
verify whether, within these settings, along with other
prognostic variables, eight clinical time points reflecting
surgical timing and responses to chemotherapy are inde-
pendent prognostic factors. Outcome measures were
morbidity, progression-free survival (PFS), and overall
long-term survival during a median 5-year follow-up.
Univariate and multivariate analyses were conducted to
identify the most significant factors related to outcome.
METHODS
Study Design
We conducted a retrospective, multicenter cohort study
in 11 tertiary Italian centers experienced in treating PSM
and ovarian cancers, over a 16-year period from December
1998 to December 2014. The Institutional Review Board
for each center approved the study procedures.
Patient Population
Data were collected by a single work group using a
custom-designed database. We only collected data for
patients whose records included complete information on
clinical and epidemiological characteristics, including age,
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, tumor markers, diagnostic techniques,
International Federation of Gynecology and Obstetrics
(FIGO) stage,24 tumor histology,25 peritoneal disease
spread according to the Peritoneal Cancer Index (PCI),26
surgical procedures used (including information on com-
plications and operative mortality according to the
Clavien–Dindo classification),27 CRS results according to
the completeness of cytoreduction (CC) score,26 HIPEC
techniques and drugs, number of adjuvant and NACT
cycles, eventual drug-induced toxicity during systemic
chemotherapy and HIPEC evaluated according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE version 4.0)28 and last com-
plete updated data on follow-up. Patients were grouped
according to primary or recurrent disease when they
underwent CRS and HIPEC. Each group was subdivided
into four subgroups according to the various time points at
which the disease was treated. Patients treated for primary
disease (FIGO stage III tumors A, B, C and stage IVB)
were subdivided as follows: Time 1, primary debulking
surgery (PDS); Time 2, interval debulking surgery (IDS)
after partial response to NACT; Time 3, IDS after no
response to NACT (stable disease); and Time 4, IDS after a
pathologic complete response (pCR) to NACT. NACT
responses were evaluated according to the Response
Evaluation Criteria in Solid Tumors (RECIST) revised
guideline version 1.1,29 and pCR was assessed as proposed
by Bo¨hm et al.30 Patients treated for recurrent disease,
regardless of FIGO stage at the primary operation, were
subdivided as follows: Time 5, first recurrence with a
progression-free interval[12 months; Time 6, first recur-
rence with a progression-free interval\12 months; Time 7,
first recurrence with a progression-free interval
[12 months in patients who underwent further
chemotherapy before CRS and HIPEC; and Time 8,
patients who underwent two or more CRS procedures for
recurrence and two or more chemotherapy lines before
CRS and HIPEC. Platinum-based chemotherapy sensitivity
was defined according to the 2010 Gynecological Cancer
Intergroup (GCIG) criteria.31 Indications for CRS plus
HIPEC were peritoneal metastatic spread from advanced or
recurrent ovarian cancer in patients younger than 75 years
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of age, with adequate cardiac, renal, hepatic and bone
marrow function, ECOG performance status 0–2 with
resectable disease, and written informed consent. Con-
traindications for CRS and HIPEC were extra-abdominal
disease, other malignancies except breast cancer, unre-
sectable disease, or patients who underwent NACT with
progressive disease and patients whose severe associated
medical conditions made them unfit for the procedure.
Statistical Analysis
Follow-up data were completed on 31 December 2015.
Patients with incomplete CRS (CC score [0) were con-
sidered as alive with disease at follow-up. Data were
analyzed using the NCSS software package (2007; NCSS,
LLC, Kaysville, UT, USA). The v2 test was used to analyze
differences in frequencies and the t test was used to analyze
differences among means. Multivariate logistic regression
analysis was used to test risk factors for postoperative
complications.
Overall survival (OS) was calculated from the date of
CRS plus HIPEC to death or 31 December 2015, and PFS,
with 95% confidence intervals (CI), was calculated to the
date when disease recurred or progressed. Data for median
follow-up were calculated as proposed by Schemper and
Smith.32 Survival was analyzed using the Kaplan–Meier
method and expressed as percentages to a maximum of
60 months, or as the median number of months. The log-
rank test and Cox regression analysis were used for uni-
variate and multivariate analysis of prognostic factors. In
the univariate analyses, prognostic factors that correlated
significantly with survival at least once were evaluated by
multivariate Cox regression analysis. p values\0.05 were
considered to indicate statistical significance.
RESULTS
Overall, 511 patients attending the 11 Italian centers met
the inclusion criteria and underwent CRS and HIPEC—226
(44.2%) for primary advanced cancer and 285 (55.8%) for
recurrent ovarian cancer (Table 1). All data supplied were
reviewed by the senior surgeon (AD).
Cytoreductive Surgery and Morbidity
At laparotomy, the mean PCI in the 511 patients was
12.7 (range 0–39), but differed significantly at the eight
time points (p\ 0.000 using the Student’s t-test). More
surgical procedures were needed for patients with primary
advanced cancer than for those with recurrent ovarian
cancer (7.8 vs. 5.7). In 72.6% of patients, surgery achieved
complete cytoreduction; the percentages for patients trea-
ted for primary advanced cancer (Times 1–4) and recurrent
ovarian cancer (Times 5–8) were similar (70.8 vs. 74%).
Surgery achieved the lowest percentage of complete
cytoreduction in patients undergoing IDS and with no
TABLE 1 Patient demographic and clinical characteristics listed according to the eight time points (511 patients)



















Age [years; mean (range)] 57.1 (29–75) 60.4 60.1 58.3 60.7 53.7 54.8 57 54.8





643 695.3 766 26.9 235.2 579 330 467
ECOG performance status
0 219 (42.9) 21 (39.6) 46 (41.4) 18 (40) 13 (76.5) 49 (51.6) 19 (54.3) 17 (34.7) 36 (34)
1 203 (39.7) 21 (39.6) 50 (45.1) 16 (35.6) 3 (17.6) 37 (39) 13 (37.1) 20 (40.8) 43 (40.6)
2 89 (17.4) 11 (20.7) 15 (13.5) 11 (24.4) 1 (5.9) 9 (9.5) 3 (8.5) 12 (24.5) 27 (25.5)
Ascites 275 (53.8) 38 (71.7) 58 (52.2) 31 (68.9) – 31 (32.6) 16 (45.7) 28 (57.1) 73 (68.9)
Histology
Serous 443 (86.7) 46 (86.8) 101 (91) 39 (86.7) 17 (100) 81 (85.3) 29 (82.9) 35 (71.4) 95 (89.6)
Other 68 (13.3) 7 (13.2) 10 (9) 6 (12.4) – 14 (14.7) 6 (17.1) 14 (28.6) 11 (10.4)
Grading
High grade 419 (82) 40 (75.5) 85 (76.6) 20 (41.4) 17 (100) 85 (89.5) 32 (91.4) 44 (89.8) 81 (76.4)
Low grade 92 (18) 13 (24.5) 26 (23.4) 25 (55.6) – 10 (10.5) 3 (8.5) 5 (10.2) 25 (23.6)
Data are expressed as n (%) unless otherwise stated
BMI body mass index, ECOG Eastern Cooperative Oncology Group
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response to NACT. The data analysis comparing complete
cytoreduction rates differed significantly at the eight time
points (p\ 0.013 using the v2 test) (Table 2). After sur-
gery, patients were transferred to an intensive care unit
(ICU) for a mean stay of 54 h (range 12–816). The mean
hospital stay was 21 days (range 8–93), and the overall
surgical morbidity rate was 44.2%. Of the 511 patients
treated, 498 survived; overall operative mortality was 2.5%
(13 cases). Multivariate logistic regression analysis iden-
tified a CC score[ 0 and the need for more than four blood
transfusions during surgery as significant risk factors for
major complications (Table 3).
Hyperthermic Intraperitonal Chemotherapy (HIPEC)
and Systemic Post-HIPEC Chemotherapy
HIPEC was conducted using the closed technique in
53.8% of cases, the open technique in 23.9% of cases, and
a semi-closed technique aided by a peritoneal cavity
expander in 22.3% of cases. In 268 of the 511 patients
(52.4%), HIPEC was administered with a single drug, i.e.
cisplatin 75 mg/m2 for 60 min in 193 patients and
oxaliplatin 460 mg/m2 for 30 min in 75 patients. In 243
patients (47.6%) cisplatin was combined with doxorubicin,
paclitaxel, and mitomycin. HIPEC induced toxicity in 28
patients (5.4%): grade 1–2 acute kidney injury in 18
patients and grade 3 leukopenia in 10 patients, which was
promptly reversed after medical treatment. Of the 498
patients who survived CRS plus HIPEC, 425 (85.3%)
underwent systemic chemotherapy (patients who were
considered platinum-sensitive received carboplatin and
paclitaxel, and those who were considered platinum-resis-
tant pegylated liposomal doxorubicin, topotecan, and, in
recent years, biologic therapies) and 73 (14.6%) received
no systemic chemotherapy for various reasons (unsuit-
able general conditions, toxicity, patient’s refusal).
Histology
In most cases (86.7%), histological examination
detected an ovarian papillary serous carcinoma in 82%
high-grade cancers (Table 1). In the 332 patients who
underwent lymphadenectomy, 41.6% had lymph node
metastases.































567 76 126 62 9 79 39 47 129
Hepatobiliary and spleno-
pancreatic resections
561 62 116 74 4 69 42 63 131
Genitourinary resections (bladder/
ureter)
35 3 5 5 – 8 2 2 10
Lymphadenectomy (pelvic/para-
aortic/inguinal)
507 69 145 46 21 61 21 45 99
Total procedures 3373 420 847 398 89 430 208 304 677
Mean procedures 6.6 7.9 7.6 8.8 5.2 4.5 5.9 6.2 6.4
PCI [mean (range)] 12.7
(0–39)
15.8 11.6 16.1 5 10.2 13.9 13.8 14.4 0.00002a
CC score
























PCI Peritoneal Cancer Index, CC completeness of cytoreduction
a Using the T-test
b Using the v2 test
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Survival
At a mean follow-up of 53.8 months, 222 of the 511 patients
enrolled in the study had died of disease (43.4%) [17 died of
causes unrelated to advanced ovarian cancer (3.3%)] and 259
are still alive—130 (25.4%) with recurrent disease and 129
(25.2%) disease-free. Kaplan–Meier survival analysis indi-
cated 5-year OS of 44.4% and PFS of 19.7%. Median OS was
52.4 months (95% CI 44.0–58.4) and PFS was 16.6 months
(95% CI 14.7–19.1). Survival analysis showed a trend for better
OS in patients treated for primary advanced ovarian cancer than
in those treated for recurrence, but significantly better PFS.
Outcome analysis in patients in whom CRS plus HIPEC was
used for primary advanced ovarian cancer showed significant
differences in OS and PFS according to the time points ana-
lyzed for that specific setting, especially in Time 3 (IDS after no
response to NACT). Similarly, survival analysis in patients
treated for recurrence showed that outcome differed signifi-
cantly at the various time points when measured as OS rather
than PFS, especially at Time 6 (first recurrence with a pro-
gression-free interval\12 months; Fig. 1). In the 511 patients,
univariate analysis (log-rank test) identified CA-125 blood
levels, ascites, extent of peritoneal spread (PCI), degree of
cytoreduction achieved (CC score), tumor grading, and various
time points when patients underwent CRS and HIPEC as
variables significantly correlated with OS. Multivariate Cox
regression analysis re-evaluating significant univariate prog-
nostic factors, identified CC score, PCI and time points at
which patients underwent CRS plus HIPEC as the most
significant factors capable of independently influencing long-
term survival (Table 4).
DISCUSSION
In this Italian multicenter study conducted over 16 years
in patients treated with CRS and HIPEC combined for
advanced ovarian cancer, multivariate analysis showed that
besides peritoneal spread (PCI) and CC score, another
equally significant independent prognostic factor influenc-
ing outcome is the time when patients undergo CRS plus
HIPEC. Even though our attempt to categorize CRS plus
HIPEC-related outcomes according to biologic behaviors
comes from retrospective data, our findings merit further
research to refine the suggested profiles.
Possibly challenging other reports on the outcomes
benefit of HIPEC,10,22,33 patients who underwent CRS plus
HIPEC for primary advanced ovarian cancer had an almost
similar or even better outcome than those treated for
recurrence (Fig. 1). Our findings agree with published
reports analyzing CRS with HIPEC,13,15 and compare well
with those using primary CRS alone.5,34–36 Analyzing our
outcomes and published data for patients in the two
Gynecologic Oncology Group randomized control trials
(114 and 172),37,38 our data, comparable mainly for
patients at Time 1 (without NACT), compare well with
those for both the control and normothermic intraperitoneal
arms, especially given that our study sample mainly


























137 (26.8) 13 (24.5) 41 (36.9) 13 (28.9) 3 (17.6) 18 (18.9) 11 (31.4) 9 (18.4) 29 (27.3) NS
Grade C IIIa
(%)
89 (17.4) 10 (18.9) 10 (9) 9 (20) 3 (17.6) 15 (15.8) 5 (14.3) 9 (18.4) 28 (26.4) NS
p value OR (Adjusted) 95% CI
Risk factors for postoperative major morbidity (Grade III–IV), multivariate analyses (logistic regression)
Independent variables
CC score 0 vs.[ 0 0.013 0.24982 0.29197–2.48208
Duration of CRS ? HIPEC (hours)
B8.6 vs.[8.6 0.047 0.79036 0.40447–0.87499
PCI B 12.7 vs.[ 12.7 0.854 0.93062 0.69562–0.83942
Blood transfusion units B4 vs.[4 0.002 0.35323 0.37162–1.70963
Bold values indicate statistical significance
NS non-significant, CC completeness of cytoreduction, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy, PCI
Peritoneal Cancer Index, OR odds ratio, CI confidence interval
a Including 13 cases (2.5%) of operative mortality
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54.1 20.2 46.8 15.2
41.4
14.7
PFS p = 0.02
OS p = 0.001
PFS p = 0.004
OS p = 0.008
PFS p = ns
T 1 - 4
T1 T2 T3 T4 T5 T6 T7 T8
T 5 - 8
40 50 60
FIG. 1 Overall survival and
progression-free survival in the






TABLE 4 Cox regression analysis of prognostic factors
Independent variables Univariate Multivariate
p-value OR (Adjusted) 95% CI p-Value
CA-125 (B498.1 vs.[498.1) 0.012 1.0481 0.7376–1.4892 0.793
Ascites (yes vs. no) 0.009 0.9409 0.6931–1.2773 0.696
PCI (B12.7 vs.[12.7) 0.000 1.9828 1.4435–2.7236 0.000
CC score (0 vs.[0) 0.000 1.6855 1.2305–2.3087 0.001
Grading (high vs. low) 0.041 1.3361 0.9232–1.9336 0.124
Time (1–8) 0.000 2.074 1.2637–3.4038 0.003
Bold values indicate statistical significance
OR odds ratio, CI confidence interval, PCI Peritoneal Cancer Index, CC completeness of cytoreduction
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In patients treated for primary ovarian disease, in con-
trast to the results of the study by Chiva et al.,34 patients
who underwent PDS (Time 1) and those who underwent
IDS after NACT (Times 2–4), both combined with HIPEC,
had a similar prognosis (OS 57.2 vs. 43.3%, median 61.2
vs. 53.2 months) [p = non-significant]. Extending current
knowledge, patients who even partly responded to NACT
(Time 2) had a significantly longer median number of
months and OS than those who did not respond (Time 3;
OS 47.6 vs. 24.5%, median 58 vs. 37.4 months; p\ 0.007
using the v2 test; Fig. 1). In line with previous reports,39–41
the few patients in whom NACT achieved a pCR (Time 4)
benefitted from particularly favorable survival after CRS
and HIPEC, as already reported for PSM from colorectal
cancer.42 Even though NACT is increasingly used as the
primary treatment for advanced ovarian cancer,35 contro-
versies persist on whether NACT might act as a driver for
chemotherapy resistance.43,44 Our therapeutically useful
finding that NACT responses significantly influence prog-
nosis in patients who undergo CRS plus HIPEC leaves
open to question whether and which patients with advanced
ovarian cancer should undergo NACT (whenever not
required by tumor burden). Nor does it specify whether
NACT non-responders (Time 3) might benefit from HIPEC
eventually combined with CRS.
For patients treated for recurrent disease, our collective
results in patients with a high peritoneal disease burden
compare well with the most recently published studies
addressing secondary CRS without HIPEC, and also
because many refer to localized ovarian recurrent dis-
ease.45–48 Pooled data for first platinum-sensitive
recurrence (Times 5 and 7) show that, together, these
patients have a significantly better OS than those treated for
their first platinum-resistance recurrence (Time 6; 49.2 vs.
23.8%; p\ 0.002 using the v2 test). Because our findings
surprisingly argue against the reported benefits of CRS
combined with HIPEC in platinum-resistant patients
(Time 6),10,14 this question remains open to further
research. Presumably, the long, 12-month cut-off we used
to define platinum-based chemotherapy sensitivity allowed
us to select truly chemotherapy-sensitive or resistant
patients. Another useful finding came from our decision to
analyze data for patients treated for first platinum-sensitive
recurrence (Times 5 and 7) separately according to whe-
ther they had undergone further chemotherapy cycles
before CRS and HIPEC (Fig. 1). Supporting previous
findings,49 our outcome data therefore suggest that patients
who have resectable platinum-sensitive recurrence should
undergo surgery without further chemotherapy.
Last, by analyzing our data in patients with advanced
ovarian cancer according to the long natural history of
disease, another finding relates to the satisfactory OS
(40.6%, median 35.7 months), our multicenter study
reports in patients who underwent CRS and HIPEC after
two or more CRS procedures and two or more
chemotherapy lines for recurrence (Time 8). Our outcome
findings compare well with published reports in patients
who underwent tertiary and quaternary CRS without
HIPEC, given that most patients had minimally extensive
peritoneal disease.50–52
Apart from its retrospective design, a limitation of this
study is that each cohort included few patients.
CONCLUSIONS
The selective information on survival provided by this
Italian multicenter study, assessed according to distinct
time points in the natural history of disease, should sim-
plify the process of selecting patients with advanced
ovarian cancer to undergo HIPEC combined with CRS,
specifying when this integrated procedure might have the
greatest outcome benefit. Our results should help interpret
findings from ongoing randomized studies investigating the
two main settings—primary and recurrent disease—and
may also suggest which patients to select to avoid bias in
future randomized trials.
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